用立即释放氧酸盐治疗麻醉症的患者的特征和治疗模式:一种倾向性得分匹配的队列研究
Melissa C Lipford1, Shahir Asfahan2, Gajinder Pal Singh2
1Mayo Clinic, Rochester, MN, USA.
概括
氧酸盐 (SXB) 是推的一种麻醉治疗方法. 这项研究发现SXB治疗或不治疗的患者之间没有显著的并发症差异,但在每晚两次服用时发现了挑战.
科学领域:
- 睡眠医学 睡眠医学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 氧化酸 (SXB) 是麻醉症的第一线治疗方法.
- 了解接受SXB的麻醉症患者的并发症和治疗模式至关重要.
研究的目的:
- 为了比较与无氧酸治疗的麻醉症患者的并发症.
- 为了确定停止或不坚持氧酸盐治疗的原因.
主要方法:
- 在1975-2020年间,电子健康记录被用来识别麻醉症患者.
- 在年龄/性别匹配的队列中,使用几率比率来比较并发症.
- 手动图表审查确定了SXB中止或遗漏剂量的原因.
主要成果:
- 在4387名麻醉症患者中,8%接受了SXB.
- 在常见的并发症 (失眠,疲劳,抑郁等) 中没有显著差异. 在接受SXB治疗和未接受治疗的队列之间发现.
- 缺乏疗效和难以醒来第二剂是SXB中止或错过剂量的主要原因.
结论:
- 随病症在接受或不接受SXB治疗的麻醉症患者之间没有显著差异.
- 尽管它是有效的,但每晚两次使用氧化酸剂量的挑战可能会导致使用不足和低于最佳的麻醉症管理.
相关概念视频
Narcolepsy
84
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
84
Management of Insomnia
229
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
229
Sedatives and Hypnotics Drugs: Miscellaneous Agents
138
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
138
REM Sleep Behavior Disorder
127
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
127
Sleep-Wake Cycles
1.2K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
1.2K
Antiepileptic Drugs: Potassium Channel Activators
138
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
138


